Imunon Inc
IMNN4.980USD
-0.120-2.35%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
9.84MCap. mercado
PérdidaP/E TTM
Más Datos de Imunon Inc Compañía
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Información de la empresa
Símbolo de cotizaciónIMNN
Nombre de la empresaImunon Inc
Fecha de salida a bolsaOct 27, 1993
Director ejecutivoDr. Stacy R. Lindborg, Ph.D.
Número de empleados25
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 27
Dirección997 Lenox Dr Ste 100
CiudadLAWRENCEVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal08648
Teléfono16098969100
Sitio Webhttps://imunon.com/
Símbolo de cotizaciónIMNN
Fecha de salida a bolsaOct 27, 1993
Director ejecutivoDr. Stacy R. Lindborg, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
2.58K
--
Ms. Kimberly Graper
Ms. Kimberly Graper
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sabby Management, LLC
3.15%
Renaissance Technologies LLC
2.23%
The Vanguard Group, Inc.
0.67%
Geode Capital Management, L.L.C.
0.51%
Tardugno (Michael H)
0.26%
Otro
93.19%
Accionistas
Accionistas
Proporción
Sabby Management, LLC
3.15%
Renaissance Technologies LLC
2.23%
The Vanguard Group, Inc.
0.67%
Geode Capital Management, L.L.C.
0.51%
Tardugno (Michael H)
0.26%
Otro
93.19%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
3.88%
Hedge Fund
2.40%
Individual Investor
1.48%
Investment Advisor
0.94%
Research Firm
0.39%
Venture Capital
0.10%
Bank and Trust
0.03%
Otro
90.78%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
52
152.78K
6.20%
-44.01K
2025Q1
50
565.85K
3.09%
-1.96M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
2023Q1
80
515.97K
6.03%
-572.90K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Renaissance Technologies LLC
10.44K
0.05%
-23.12K
-68.89%
Mar 31, 2025
The Vanguard Group, Inc.
48.81K
0.23%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
143.44K
0.67%
+3.93K
+2.82%
Mar 31, 2025
Tardugno (Michael H)
73.71K
0.35%
+4.57K
+6.61%
May 13, 2025
Fritz (Frederick J)
11.77K
0.06%
--
--
May 13, 2025
BlackRock Institutional Trust Company, N.A.
58.22K
0.27%
--
--
Mar 31, 2025
Braun (Donald P)
25.60K
0.12%
--
--
May 13, 2025
Le (Goff Corinne)
53.00K
0.25%
--
--
May 13, 2025
Lindborg (Stacy R)
28.06K
0.13%
--
--
May 13, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Fecha
Tipo
Relación
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
